

# UNITED STATES PATENT AND TRADEMARK OFFICE



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
09/743,726	04/12/2001	Richard A. Gambale	B0410/7278	7561	
22832	7590 11/21/2003		EXAMINER		
KIRKPATRICK & LOCKHART LLP			MENDEZ, MANUEL A		
75 STATE ST BOSTON, M	REET A 02109-1808		ART UNIT	PAPER NUMBER	
,			3763	2	
			DATE MAILED: 11/21/2003	19	

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	I Ameliana (I)				
	Application No.	Applicant(s)				
Office Astion Commons	09/743,726	GAMBALE ET AL.				
Office Action Summary	Examiner	Art Unit				
	Manuel Mendez	. س ک				
The MAILING DATE of this communication appears on the cover sheet with the correspond nce address Period for Reply						
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.  - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.  - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.  - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.  - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).  - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).  Status						
1) Responsive to communication(s) filed on 25 Au	<u>ıgust 2003</u> .					
2a) This action is <b>FINAL</b> . 2b) ⊠ This a	action is non-final.					
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.						
Disposition of Claims						
<ul> <li>4)  Claim(s) 1-11 is/are pending in the application.</li> <li>4a) Of the above claim(s) is/are withdrawn from consideration.</li> <li>5)  Claim(s) 9 and 11 is/are allowed.</li> <li>6)  Claim(s) 1,2,5-8 and 10 is/are rejected.</li> <li>7)  Claim(s) 3 and 4 is/are objected to.</li> <li>8)  Claim(s) are subject to restriction and/or election requirement.</li> </ul>						
Application Papers						
9) The specification is objected to by the Examiner.  10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.  Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).  11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.						
Priority under 35 U.S.C. §§ 119 and 120						
<ul> <li>12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).</li> <li>a) ☐ All b) ☐ Some * c) ☐ None of:</li> <li>1. ☐ Certified copies of the priority documents have been received.</li> <li>2. ☐ Certified copies of the priority documents have been received in Application No</li> <li>3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).</li> <li>* See the attached detailed Office action for a list of the certified copies not received.</li> <li>13) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application) since a specific reference was included in the first sentence of the specification or in an Application Data Sheet.</li> <li>37 CFR 1.78.</li> <li>a) ☐ The translation of the foreign language provisional application has been received.</li> <li>14) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121 since a specific reference was included in the first sentence of the specification or in an Application Data Sheet. 37 CFR 1.78.</li> </ul>						
Attachment(s)						
Notice of References Cited (PTO-892)     Notice of Draftsperson's Patent Drawing Review (PTO-948)     Information Disclosure Statement(s) (PTO-1449) Paper No(s) 9 8	5) 🔲 Notice of Informal F	r (PTO-413) Paper No(s) Patent Application (PTO-152)				

Art Unit: 3763

### **DETAILED ACTION**

## Claim Rejections - 35 USC § 112

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claim 10 recites the limitation "implant device" in lines 6 and 7. There is insufficient antecedent basis for this limitation in the claim.

## Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -


- (b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.
- (e) the invention was described in (1) an application for patent, published under section 122(b), by another filed in the United States before the invention by the applicant for patent or (2) a patent granted on an application for patent by another filed in the United States before the invention by the applicant for patent, except that an international application filed under the treaty defined in section 351(a) shall have the effects for purposes of this subsection of an application filed in the United States only if the international application designated the United States and was published under Article 21(2) of such treaty in the English language.
- (e) the invention was described in a patent granted on an application for patent by another filed in the United States before the invention thereof by the applicant for patent, or on an international application by another who has fulfilled the requirements of paragraphs (1), (2), and (4) of section 371(c) of this title before the invention thereof by the applicant for patent.

The changes made to 35 U.S.C. 102(e) by the American Inventors Protection Act of 1999 (AIPA) and the Intellectual Property and High Technology Technical Amendments Act of 2002 do not apply when the reference is a U.S. patent resulting directly or indirectly from an international application filed before November 29, 2000.

Art Unit: 3763

Therefore, the prior art date of the reference is determined under 35 U.S.C. 102(e) prior to the amendment by the AIPA (pre-AIPA 35 U.S.C. 102(e)).


Claim 1 is rejected under 35 U.S.C. 102(b) as being anticipated by Reed, U.S. Patent No. 3,443,561. The cited patent discloses a pellet containing a therapeutic agent; a flexible, implantable body having a hollow interior configured to receive and retain the pellet within the interior after the body has been implanted within tissue.



Figures 1-3 show a pellet containing a therapeutic agent; a flexible, implantable body having a hollow interior configured to receive and retain the pellet within the interior after the body has been implanted within tissue.

Art Unit: 3763

Claim 5 is rejected under 35 U.S.C. 102(b) as being anticipated by Billeter, et al., U.S. Patent No. 4,731,054. The cited patent discloses a pellet containing a therapeutic agent; a flexible and implantable body defining an interior sized to accept the pellet and having proximal and distal ends; wherein, the proximal end is sized to accept the pellet and the body further having at least one opening sized to permit bodily fluid to enter the interior but sized to prevent the pellet from exiting the interior (see figures 1-4 below).



Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the

Application/Control Number: 09/743,726 Page 5


Art Unit: 3763

invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).


Claims 2, 6-8, and 10 are rejected under 35 U.S.C. 103(a) as being unpatentable over Billeter, et al., U.S. Patent No. 4,731,054 in view of Pryor, et al., U.S. Patent No. 5,062,829 and Gast, et al., U.S. Patent No. 5,984,890. The Billeter, et al. Patent does not disclose an implantable body comprising a helical spring and/or an obturator/insertion device combination.

Art Unit: 3763



In figures 1 and 2, Pryor, et al., shows an agent delivery system comprising a helical spring in combination with an insertion device. Moreover, it is the examiner's opinion, that it is well known in the art to use obturators with cutting edges to cut skin surfaces in order to facilitate the insertion of delivery systems into the body.

Art Unit: 3763



In order to support the above assertion, Gast, et al., shows in figure 2 an insertion/obturator device for the insertion/placement of solid materials into the body. Based on the teachings of Pryor, et al., and Gast, et al., for a person of ordinary skill in the art, it would have been considered obvious to design a delivery device with the shape of helical coil and capable of being inserted into the body using an insertion/obturator device. Accordingly, such enhancements would have been considered obvious design alternatives.

#### Allowable Subject Matter

Claims 9 and 11 are allowable over the prior art of record. The examiner of record respectfully requests applicant to review the cited claims for minor antecedent basis problems.

Claims 3 and 4 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims.

Art Unit: 3763

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Manuel Mendez whose telephone number is 703-308-2221. The examiner can normally be reached on 0730-1800 hrs.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Mr. Brian Casler can be reached on 703-308-3552. The fax phone number for the organization where this application or proceeding is assigned is 783-305-3590.

Manuel Mendez Primary Examiner Art Unit 3763 Page 8